Results 81 to 90 of about 2,336 (164)

Development of a Novel Shigella Quadrivalent Conjugate Vaccine Using Shigella O-Polysaccharide and IpaB Carrier Protein

Vaccines
Background/Objectives: Shigella is the leading bacterial cause of diarrheal disease worldwide. Although multiple vaccine candidates are under development and in clinical trials, no Shigella vaccine is currently available on the market. Shigella comprises
Shangdong Guo, Richa Puri, Harshita Seth, Neza Chowdhury, Gowri Chellappan, Florence Seal, Yutai Zhao, Giriraj Chalke, Aakriti Bajracharya, Chloe Wright, Winston Umakanth Balasundaram, Rashmi Ghayal, Dimple Machado, Jen Gan, Geetha Karengil, Gowthami Jagruthi Penumaka, Connor Shay, Chathuranga Siriwardhana, Anup Datta, Subhash V. Kapre   +19 more
doaj   +1 more source

Discovery of Oligosaccharide Antigens for Semi-Synthetic Glycoconjugate Vaccine Leads against Streptococcus suis Serotypes 2, 3, 9 and 14*. [PDF]

Angew Chem Int Ed Engl, 2021
Zhang S, Sella M, Sianturi J, Priegue P, Shen D, Seeberger PH.   +5 more
europepmc   +1 more source

Maintained partial protection against <i>Streptococcus pneumoniae</i> despite B-cell depletion in mice vaccinated with a pneumococcal glycoconjugate vaccine. [PDF]

Clin Transl Immunology, 2022
Ercoli G, Ramos-Sevillano E, Pearce E, Ragab S, Goldblatt D, Weckbecker G, Brown JS.   +6 more
europepmc   +1 more source

Multicomponent Gold-Linked Glycoconjugate Vaccine Elicits Antigen-Specific Humoral and Mixed T_H1-T_H17 Immunity, Correlated with Increased Protection against Burkholderia pseudomallei. [PDF]

mBio, 2021
Tapia D, Sanchez-Villamil JI, Stevenson HL, Torres AG.   +3 more
europepmc   +1 more source

Rational Design of a Glycoconjugate Vaccine against Group A Streptococcus. [PDF]

Int J Mol Sci, 2020
Di Benedetto R, Mancini F, Carducci M, Gasperini G, Moriel DG, Saul A, Necchi F, Rappuoli R, Micoli F.   +8 more
europepmc   +1 more source

Retaining the structural integrity of disulfide bonds in diphtheria toxoid carrier protein is crucial for the effectiveness of glycoconjugate vaccine candidates. [PDF]

Chem Sci, 2022
Carboni F, Kitowski A, Sorieul C, Veggi D, Marques MC, Oldrini D, Balducci E, Brogioni B, Del Bino L, Corrado A, Angiolini F, Dello Iacono L, Margarit I, Romano MR, Bernardes GJL, Adamo R.   +15 more
europepmc   +1 more source

GMMA as adjuvant and carrier for mucosal delivery of group A streptococcus glycoconjugate vaccine. [PDF]

Hum Vaccin Immunother
Ozanne J, Saydam M, Palmieri E, Di Benedetto R, Aktar A, Carducci M, Rovetini L, Rossi O, Shaw HA, Micoli F, Mawas F.   +10 more
europepmc   +1 more source

Total synthesis of the capsular polysaccharide repeating unit towards the development of a glycoconjugate vaccine against <i>Klebsiella pneumoniae</i> ST512. [PDF]

Beilstein J Org Chem
Zhang S, Daněk O, Seeberger PH.
europepmc   +1 more source

Preclinical development of a well-defined semisynthetic glycoconjugate vaccine against <i>Haemophilus influenzae</i> type b. [PDF]

Sci Adv
Han W, Qin C, Tong W, Yang K, Tian X, Zhang JR, Liu J, Seeberger PH, Hu J, Yin J.   +9 more
europepmc   +1 more source

Synthesis and Immunological Evaluation of Pel-Derived Glycoconjugate Vaccine Candidates against <i>Pseudomonas aeruginosa</i>. [PDF]

JACS Au
Wu DY, Bino LD, Romagnoli G, van der Marel GA, Adamo R, Romano MR, Codée JDC.   +6 more
europepmc   +1 more source